Stoke Therapeutics Presents Data Related to the Ongoing Clinical Development of STK-001 for the Treatment of Dravet Syndrome at the 35th International Epilepsy Congress
DUBLIN--(BUSINESS WIRE)--Sep 5, 2023--
Source: eagletribune.com
Page 6 - Targeted Augmentation News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Targeted Augmentation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Targeted Augmentation Today - Breaking & Trending Today
Stoke Therapeutics Presents Data Related to the Ongoing Clinical Development of STK-001 for the Trea
– Data from multiple ongoing clinical studies of STK-001 show reductions in convulsive seizure frequency and improvements in cognition and behavior in children and adolescents with Dravet syndrome –– Data support the potential for STK-001 to be the first disease-modifying treatment for Dravet syndrome –– New pharmac...
Source: pharmiweb.com
This Under-the-Radar Growth Stock Could Soar by 277%, According to Wall Street
This small-cap biotech might be a hidden gem.
Source: fool.com
This Under-the-Radar Growth Stock Could Soar by 277%, According to Wall Street
This small-cap biotech might be a hidden gem.
Source: fool.com
Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates
– STK-001: Additional data from patients treated with single and multiple doses along with data from open-label extension studies anticipated in Q1 2024 – – STK-001: Company plans to share...
Source: marketscreener.com